COVID-19
Conditions
Brief summary
Passive immunization with immunoglobulins is occasionally used as therapy for the treatment of viral infectious diseases. Immunoglobulins are used for the treatment of CMV disease, and is effective as prophylaxis when given soon after exposure to varicella zoster virus, rabies, and hepatitis B virus. Neutralizing antibodies against MERS, SARS-CoV-1 and SARS-CoV-2 have been shown to be present in patients previously infected with MERS, SARS-CoV-1 and SARS-CoV-2 respectively. During the 2003 SARS outbreak in Hong-Kong,a non-randomized study in hospitalized SARS patients showed that treatment with convalescent plasma (convP) from SARS-recovered donors significantly increased the day 22 discharge rate and decreased mortality. A study in non-human primates showed that rhesus macaques could not be re-infected with SARS-CoV-2 after primary infection. With no proven effective therapy against COVID, this study will evaluate the safety and efficacy of convalescent plasma from COVID-recovered donors as a treatment for hospitalized patients with symptomatic COVID-19. The study will focus on patients who tested positive for SARS-CoV-2 in the last 96 hours before inclusion Primary objectives • Decrease overall mortality in patients within COVID disease Study design: This trial is a randomized comparative trial. Patients will be randomized between the infusion of 300mL of convP with standard of care. Patient population: Patients with PCR confirmed COVID disease, age \>18 years Donors will be included with a known history of COVID who have been asymptomatic for at least 14 days. Intervention: 300mL of convP Duration of treatment: ConvP will be given as a one-time infusion Duration of follow up: For the primary endpoint: until discharge or death before day 60, whichever comes first. For the secondary endpoints (with separate consent) up to 1 year. Target number of patients: 426 Target number of donors: 100 Expected duration of accrural: 36 months
Detailed description
Secondary (exploratory) objectives * Evaluate the effect of 300ml convP on hospital stay * Evaluate the change of the 8-point WHO COVID19 disease severity scale on day 15 and 30 * Evaluate the change of the 8-point WHO COVID19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer (PRNT50) \<80 * Evaluate the effect of 300ml convP on mortality in patients admitted to the ICU * Evaluate the effect of 300ml plasma therapy on hospital days for patients admitted to the ICU within 24 hours after admission * Evaluate the impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways * Evaluate the difference in effect of convP on mortality in patients with a duration of symptoms \< or \> the median duration of symptoms in the study population * Evaluate the impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer * Safety of convP therapy * Evaluate the impact of covP on long-term lung function
Interventions
BIOLOGICALConvalescent plasma
Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID. Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products
Sponsors
Prothya Biosolutions
Erasmus Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This trial is a randomized comparative trial. Patients will be randomized between the infusion of 300mL of convP versus the standard of care.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with PCR confirmed COVID disease * Admitted to the hospital * The most recent PCR positive sample is \<96hrs old * Written informed consent by patient or legal patient representative * Age at least 18 years
Exclusion criteria
* Participation in another intervention trial on the treatment of COVID-19 that falls under the Dutch law human research (WMO) and in which individual patients are randomized to different treatment options * Known IgA deficiency * Invasive ventilation for already \>96 hours Donors: Eligibility for plasma donation Inclusions Criteria: * A history of COVID infection that was documented by PCR * Known ABO-Resus(D) blood group * A screening for irregular antibodies with a titer ≤ 1:32 * Asymptomatic for at least 14 days * Written informed consent regarding the plasmapheresis procedure * Tested negative for HIV, HBV, HCV, HEV, HTLV and syfilis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first | until hospital discharge or a maximum of 60 days whichever comes first | the mortality in the 300ml convP group will be compared with the control arm |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Impact of 300ml convP on weaning from oxygen therapy | until hospital discharge or a maximum of 60 days whichever comes first | A patient will be considered weaned from oxygen therapy when the patient did not receive oxygen for at least 24 hours. |
| Impact of 300ml convP on overall mortality in patients admitted to the ICU within 24 hours after admission | until hospital discharge or a maximum of 60 days whichever comes first | the overall mortality in hospital days in patients admitted tot the ICU within 24 hours after admission in the 300ml convP group will be compared with the patients admitted tot the ICU within 24 hours after admission in the control arm |
| Difference in the effect of convP on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population | hospital discharge or a maximum of 60 days whichever comes first | The mortality in patients with a duration of symptoms less than the median duration of symptoms in the study population will be compared with the mortality in patients with a duration of symptoms more than the median duration of symptoms in the study population |
| Impact of 300ml convP therapy on ICU days in patients admitted to the ICU within 24 hours after admission | Until hospital discharge, estimated average 4 weeks | the ICU days in hospital days in patients admitted to the ICU within 24 hours after admission in the 300ml convP group will be compared with the patients admitted tot the ICU within 24 hours after admission in the control arm |
| Impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways | until hospital discharge, estimated average 2 weeks | airway samples will be taken on day 1 - 3 - 5 - 7 - 10 - 14 - and at discharge |
| Impact of 300ml convP therapy on hospital days | until hospital discharge or a maximum of 60 days whichever comes first | the hospital days in the 300ml convP group will be compared with the control arm |
| Safety of convP therapy | until hospital discharge or a maximum of 60 days whichever comes first | Evaluation of Severe Adverse Events and transfusion related adverse events |
| Change of the 8-point WHO COVID19 disease severity scale on day 15 | until day 15 | The WHO COVID19 disease severity scale on day 15 will be compared with the WHO COVID19 disease severity scale on day 1 |
| Change of the 8-point WHO COVID19 disease severity scale on day 30 | until day 30 | The WHO COVID19 disease severity scale on day 30 will be compared with the WHO COVID19 disease severity scale on day 1 and day 15 |
| Change of the 8-point WHO COVID19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer (PRNT50) <80. | until day 15 | The WHO COVID19 disease severity scale on day 15 will be compared with the WHO COVID19 disease severity scale on day 1 in patients with a baseline neutralizing antibody titer (PRNT50) \<80. |
| Impact of plasma therapy on risk of long-term structural lung damage and lung function | up to 12 months after plasma transfusion | Low dose CT and lung function is done 6 weeks after discharge and if abnormal again 3 months after discharge. |
| Impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer | until hospital discharge, extimated average 2 weeks | Blood wil be drawn at day 1, day 7 and day 14 |
Countries
Netherlands
Outcome results
None listed